TNFRSF9 and neoplasm: When comparing anti-tumor activity between the anti-4-1BB/anti-PD-1 and the anti-PD-1/anti-LAG-3 in the B16-F10 melanoma mouse model, tumor regression occurred in animals receiving anti-PD-1 anti-4-1BB was more concomitantly [358].